Understanding the Impact of the DATA Waiver's Elimination with Dr. Stuart Gitlow
The elimination of the waiver will allow more healthcare professionals to prescribe buprenorphine, resulting in a dramatic drop in morbidity and mortality. But we could be in a situation where doctors are told not to prescribe it because a small percentage of it is ending up on the street, even though you're helping thousands and thousands of people with opioid use disorder.
What happens when a key regulation in addiction medicine is suddenly lifted? In this episode of 'Drug Diversion Insights with Terri Vidals', Dr. Stuart Gitlow, a seasoned physician with three decades of experience in addiction medicine, sheds light on the history and recent elimination of the DATA Waiver (also known as the X-Waiver). Dr. Gitlow explains how this waiver initially regulated the use of methadone in opioid treatment programs and how its removal could reshape the landscape of addiction treatment.
He shares personal observations on the benefits of buprenorphine, a medication-assisted treatment for opioid use disorder, and why its broader accessibility could be a game-changer in reducing opioid-related deaths. However, Dr. Gitlow also warns of potential pitfalls, such as the risk of drug diversion and the need for continuous care and monitoring. This episode is a must-listen for anyone interested in understanding the complexities of addiction treatment and the implications of regulatory changes.
Whether you're a healthcare professional or someone affected by the opioid crisis, Dr. Gitlow's insights offer valuable perspectives on navigating this evolving field.